Publication Name	World Journal of Gastroenterology
Manuscript ID	5390
Country	Japan

Received	2013-09-04 17:09
Peer-Review Started	2013-09-05 09:07
To Make the First Decision	2013-12-26 11:23
Return for Revision	2013-11-14 10:42
Revised	2013-11-20 09:02
Second Decision	2014-02-27 11:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-02-27 11:36
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-19 10:39
Publish the Manuscript Online	2014-04-17 13:27

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
Manuscript Source	Invited Manuscript
All Author List	Koji Miyahara, Kazuhiro Nouso and Kazuhide Yamamoto
Funding Agency and Grant Number
Corresponding Author	Koji Miyahara, MD, PhD, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama 700-8558, Japan. mkojisup@yahoo.co.jp
Key Words	Biomarker; Molecular targeted therapy; Clinical trial; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Sorafenib
Core Tip	Sorafenib is the only systemic therapy proven to have a positive effect on survival and to be well tolerated in patients with advanced hepatocellular carcinoma (HCC). We summarize the most current status of sorafenib therapy, focusing on (1) safety and efficacy of sorafenib for advanced HCC; (2) biomarkers predicting efficacy of sorafenib; (3) expanded application for the treatment of non-advanced HCC; (4) sorafenib efficacy beyond radiological progression; and (5) novel therapeutics and hepatic arterial infusion chemotherapy.
Publish Date	2014-04-17 13:27
Citation	Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159
URL	http://www.wjgnet.com/1007-9327/full/v20/i15/4151.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i15.4151

Full Article (PDF)	WJG-20-4151.pdf
Full Article (Word)	WJG-20-4151.doc
Manuscript File	5390-Review.docx
Answering Reviewers	5390-Answering reviewers.pdf
Copyright License Agreement	5390-Copyright assignment.pdf
Peer-review Report	5390-Peer review(s).pdf
Scientific Editor Work List	5390-Scientific editor work list.doc